Gapping up
In reaction to earnings/guidance:
- EPAC +2.8%, GMS +2.5%
Other news:
- ERAS +6.9% (FDA issues orphan drug designation for treatment of malignant glioma)
- ROIV +5.2% (Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study)
- AAOI +4.4% (enters into supply agreement with MSFT to provide design and assembly services)
- IVVD +4.4% (Initial Data from Ongoing Phase 1 Clinical Trial of VYD222 a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People)
- MRNS +4.3% (patent granted by USPTO)
- KURA +3.5% (Director bought 50000 shares)
- GVA +2.7% (awarded a $48 mln contract)
- OSG +2% (awarded government contract)
- NRG +1.9% (provides strategic update and announces new capital allocation framework; increased share repurchase authorization to $2.7 billion through 2025)
- LOGI +1.4% (authorizes new $1 bln share repurchase program)
Analyst comments:
- ADC +0.8% (upgraded to Buy from Neutral at Mizuho)